{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:26:11Z","timestamp":1793949971462,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,11,6]],"date-time":"2027-11-06T00:00:00Z","timestamp":1825459200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30CA15083"],"award-info":[{"award-number":["P30CA15083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtho.2026.103993","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:12:12Z","timestamp":1781968332000},"page":"103993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement"],"prefix":"10.1016","volume":"21","author":[{"given":"Shinichiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Mopuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ayers-Ringler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan W.","family":"Asmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Kosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103993_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/2159-8290.CD-24-0088","article-title":"Elucidating the cell surfaceome to accelerate cancer drug development","volume":"14","author":"Geri","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103993_bib2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","author":"Lou","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.jtho.2026.103993_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2026.103993_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103993_bib5","first-page":"91","article-title":"Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment","volume":"4","author":"Rajasekaran","year":"2015","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jtho.2026.103993_bib6","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2026.103993_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New era for malignant pleural mesothelioma: updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/PAS.0000000000000864","article-title":"A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2026.103993_bib10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/10935266211021222","article-title":"Malignant mesothelioma with EWSR1-ATF1 fusion in two adolescent male patients","volume":"24","author":"Ren","year":"2021","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.jtho.2026.103993_bib11","doi-asserted-by":"crossref","first-page":"9165","DOI":"10.3390\/ijms24119165","article-title":"Target therapy in malignant pleural mesothelioma: hope or mirage?","volume":"24","author":"Borea","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2026.103993_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103993_bib14","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/cancers15245787","article-title":"Current state-of-the-art therapy for malignant pleural mesothelioma and future options centered on immunotherapy","volume":"15","author":"Cedres","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.103993_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.103993_bib16","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib17","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103993_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jtho.2025.03.044","article-title":"Misleading interpretations of the MET gene acronym: over 15 years of confusion in scientific publications and a call for reaffirming the original gene nomenclature","volume":"20","author":"Religa","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jtho.2026.103993_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103993_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2105-15-224","article-title":"MAP-RSeq: Mayo analysis pipeline for RNA sequencing","volume":"15","author":"Kalari","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jtho.2026.103993_bib22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","article-title":"Single-cell view of tumor microenvironment gradients in pleural mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103993_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/19420862.2016.1249079","article-title":"Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells","volume":"9","author":"Grugan","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.jtho.2026.103993_bib24","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103993_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103993_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib28","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103993_bib29","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib30","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103993_bib31","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103993_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41698-024-00682-y","article-title":"Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression","volume":"8","author":"Rivera-Soto","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib33","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"J\u00e4nne","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103993_bib34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.jtho.2026.103993_bib36","article-title":"The predictive and prognostic nature of programmed death-ligand 1 in malignant pleural mesothelioma: a systematic literature review","volume":"3","author":"Mansfield","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103993_bib37","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib38","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2026.103993_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1535-7163.MCT-24-0308","article-title":"TEAD-independent cell growth of hippo-inactive mesothelioma cells: unveiling resistance to TEAD inhibitor K-975 through MYC signaling activation","volume":"24","author":"Akao","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103993_bib40","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202503241","article-title":"Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma","volume":"8","author":"Cunningham","year":"2025","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.jtho.2026.103993_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18330","article-title":"YAP\/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma","volume":"28","author":"Papavassiliou","year":"2024","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtho.2026.103993_bib42","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/cancers13071561","article-title":"NF2 and canonical hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.103993_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","article-title":"NF2 alteration in mesothelioma","volume":"5","author":"Sekido","year":"2023","journal-title":"Front Toxicol"},{"key":"10.1016\/j.jtho.2026.103993_bib44","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103993_bib45","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP-deleted mesothelioma: in vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtho.2026.103993_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103993_bib47","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/2767-9764.CRC-24-0107","article-title":"Exploration of immune-modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma","volume":"4","author":"Lim","year":"2024","journal-title":"Cancer Res Commun"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426004466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426004466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:37:43Z","timestamp":1793947063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426004466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1556086426004466"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103993","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103993"}}